Chevy Chase Trust Holdings LLC Has $24.84 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Chevy Chase Trust Holdings LLC reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 46,008 shares of the company’s stock after selling 428 shares during the period. Chevy Chase Trust Holdings LLC’s holdings in IDEXX Laboratories were worth $24,841,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Valley National Advisers Inc. raised its holdings in IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after purchasing an additional 22 shares during the last quarter. Riverview Trust Co bought a new position in shares of IDEXX Laboratories in the 1st quarter valued at about $26,000. DSM Capital Partners LLC acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $33,000. Private Wealth Management Group LLC bought a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $34,000. Finally, Venturi Wealth Management LLC lifted its holdings in IDEXX Laboratories by 226.3% in the fourth quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock valued at $34,000 after buying an additional 43 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director Bruce L. Claflin sold 200 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the transaction, the director now directly owns 161 shares of the company’s stock, valued at approximately $87,068.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.18% of the company’s stock.

IDEXX Laboratories Stock Up 0.5 %

IDXX stock traded up $2.19 during mid-day trading on Wednesday, hitting $480.08. 143,227 shares of the company were exchanged, compared to its average volume of 466,521. The firm has a market cap of $39.65 billion, a P/E ratio of 46.45, a P/E/G ratio of 3.95 and a beta of 1.32. IDEXX Laboratories, Inc. has a 1-year low of $372.50 and a 1-year high of $583.39. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57. The firm’s 50 day simple moving average is $499.62 and its 200 day simple moving average is $523.27.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. The firm had revenue of $964.10 million during the quarter, compared to analyst estimates of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Morgan Stanley cut their target price on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. Barclays decreased their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, June 14th. Finally, Stifel Nicolaus reduced their price objective on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research note on Monday, June 24th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $586.63.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.